surfac
display
immobil
protein
commonli
refer
protein
biochip
promis
multitud
applic
quick
comprehens
biomark
detect
clinic
sampl
proteomewid
interact
screen
applic
drug
discoveri
advantag
protein
biochip
tradit
method
elisa
low
sampl
consumpt
inher
aptitud
toward
miniatur
case
protein
microarray
display
multipl
protein
simultan
characterist
translat
abil
process
mani
thousand
sampl
parallel
featur
particularli
import
proteomewid
analysi
manufactur
protein
microarray
take
advantag
earlier
success
dna
microarray
much
equip
use
dnamicroarray
fabric
analysi
also
appli
protein
microarray
howev
owe
delic
sensit
natur
protein
transit
dna
protein
microarray
complic
requir
special
tailor
proteinimmobil
method
ensur
protein
integr
function
immobil
protein
biochip
display
protein
featur
defin
geometri
requir
even
complic
manufactur
approach
howev
much
progress
made
field
recent
review
chemic
strategi
gener
protein
biochip
herein
present
applic
protein
biochip
select
area
biomed
biotechnolog
research
name
proteom
research
biomark
detect
drug
discoveri
protein
microarray
display
larg
number
differ
protein
attract
bioanalyt
platform
great
potenti
biomed
analysi
proteom
research
one
advanc
exampl
applic
protein
microarray
date
macbeath
cowork
investig
phosphoryl
state
erbbreceptor
kinas
function
protein
microarray
epiderm
growth
factor
receptor
egfr
wellstudi
member
erbb
famili
known
potent
oncogen
studi
depth
oncogen
protect
role
cancer
elucid
role
macbeath
cowork
first
identifi
tyrosin
phosphoryl
site
use
tandem
mass
spectrometri
approach
subsequ
microarray
display
ptb
domain
microarray
creat
aldehydemodifi
glass
slide
probe
fluoresc
label
phosphopeptid
repres
identifi
phosphoryl
site
approach
enabl
construct
quantit
interact
network
new
interact
dnabind
protein
believ
play
role
apoptosi
identifi
figur
author
attribut
progress
develop
proteinimmobil
strategi
method
made
protein
biochip
increasingli
access
integr
assay
analysi
platform
biomed
biotechnolog
research
substanti
expand
repertoir
method
avail
proteom
biomark
research
drug
develop
minireview
highlight
select
develop
applic
protein
biochip
field
protect
role
cancer
abil
form
benign
heterodim
erbb
receptor
thu
decreas
amount
oncogen
heterodim
egfr
buffer
mechan
gong
et
al
use
function
protein
microarray
profil
proteinprotein
proteindna
interact
global
level
plant
arabidopsi
thaliana
start
fast
nitrocellulos
membran
slide
construct
microarray
display
transcript
factor
tf
arabidopsi
thaliana
obtain
express
yeast
microarray
probe
fluoresc
label
oligonucleotid
repres
known
bind
site
tf
famili
way
author
confirm
known
dnatf
interact
identifi
new
interact
previous
uncharacter
tf
famili
second
set
experi
protein
microarray
display
tf
use
investig
tf
bind
socal
even
element
ee
ee
motif
overrepres
eveningphas
gene
connect
daytimeregul
express
probe
tf
microarray
fluoresc
label
ee
oligonucleotid
gong
et
al
identifi
eemotifbind
candid
previous
found
show
clockregul
express
final
author
probe
microarray
display
tf
biotinyl
gsttag
gst
glutathion
stransferas
tf
known
posit
regul
photomorphogenesi
detect
fluoresc
label
streptavidin
result
identif
reproduc
interact
yeast
twohybrid
assay
four
interact
confirm
randomli
chosen
hit
result
suggest
bind
differ
protein
differ
target
motif
consist
function
key
regul
lightsign
network
arabidopsi
thaliana
gener
wholeproteom
microarray
technic
challeng
larg
number
function
protein
involv
need
isol
complic
matter
whole
proteom
challeng
analyz
repres
snapshot
complet
protein
repertoir
given
set
cell
given
moment
time
protein
differ
structur
function
interact
local
turnov
rate
also
notabl
dynam
rang
abund
copi
human
cell
copi
plasma
howev
advantag
use
wholeproteom
protein
microarray
proteom
research
especi
abil
process
thousand
sampl
parallel
far
outweigh
difficulti
face
prepar
use
protein
microarray
biomark
discoveri
receiv
particular
attent
research
cancer
medicin
biomark
understood
molecul
set
molecul
link
defin
biolog
state
cell
organ
organ
biolog
state
may
exampl
reflect
certain
diseas
state
cancer
identif
biomark
earlystag
cancer
could
lead
improv
therapi
surviv
rate
patient
antibodi
array
commonli
use
protein
array
biomark
discoveri
proteom
research
phase
protein
array
fppa
reversephas
protein
array
rppa
employ
figur
case
fppa
specif
antibodi
immobil
specif
spot
microarray
bind
protein
sampl
exampl
human
serum
ideal
multipl
protein
detect
simultan
one
array
protein
usual
detect
fluoresc
use
either
dyelabel
secondari
antibodi
label
sampl
protein
rppa
multipl
sampl
exampl
tissu
lysat
patient
sera
immobil
directli
spot
microarray
analyz
singl
label
antibodi
specif
certain
protein
interest
rppa
particularli
wellsuit
analysi
posttransl
modif
approach
especi
import
analysi
proteinsign
network
often
involv
cancer
modif
difficult
analyz
convent
protein
microarray
deriv
recombin
protein
sinc
frequent
introduc
protein
protein
express
bacteria
yeast
therefor
rppa
promis
tool
clinic
diagnost
rppa
follow
advantag
small
sampl
amount
need
label
cellular
protein
lysat
requir
quantit
detect
possibl
multitud
differ
sampl
compar
high
throughput
multiplex
analysi
possibl
posttransl
modif
phosphoryl
detect
howev
limit
rppa
possibl
detect
known
target
investig
perform
rppa
tibe
et
al
use
celllys
sampl
leukemia
patient
print
rppa
microarray
fast
nitrocellulos
slide
analyz
appropri
antibodi
bind
detect
secondari
antibodi
fluoresc
readout
author
valid
step
rppasampl
prepar
readout
appropri
analysi
techniqu
exampl
western
blot
thorough
comparison
abl
demonstr
power
reliabl
rppa
rapid
analysi
larg
number
biomark
larg
number
antibodi
gener
proteom
employ
polypeptid
sequenc
known
protein
epitop
signatur
tag
prest
figur
sequenc
produc
heterolog
express
open
read
frame
orf
identifi
genom
studi
prest
peptid
spot
directli
microarray
antibodi
prest
peptid
produc
highthroughput
immun
prestpeptid
microarray
use
specif
profil
antibodi
gener
use
applic
antibodi
array
highli
limit
avail
qualiti
antibodi
step
gener
use
antibodi
microarray
involv
qualiti
control
valid
independ
method
avoid
falseposit
falseneg
hit
reduc
bia
moreov
essenti
antibodi
display
suffici
high
specif
affin
constant
well
suitabl
dynam
rang
factor
influenc
experiment
condit
consequ
paramet
immobili
figur
quantit
interact
network
tyrosin
kinas
associ
erbb
famili
receptor
determin
use
protein
microarray
display
ptb
domain
ptbdomain
microarray
probe
fluoresc
label
phosphopeptid
repres
tyrosin
phosphoryl
site
erbb
kinas
microarray
readout
peptid
bind
base
fluoresc
interact
network
construct
quantit
interact
data
obtain
reprint
refer
permiss
elsevi
zation
condit
ph
valu
temperatur
storag
condit
play
import
role
need
optim
valid
ensur
reliabl
result
biochip
experi
antibodi
microarray
appli
success
cancer
research
exampl
sanchezcarbayo
et
al
util
antibodi
array
contain
antibodi
distinguish
patient
bladder
cancer
control
patient
n
correct
classif
rate
predict
inform
bladdercanc
patient
obtain
basi
microarray
data
surviv
rate
furthermor
serum
protein
identifi
could
possibl
serv
biomark
classifi
certain
bladdertumor
stage
result
obtain
support
addit
data
immunohistochemistri
tissu
microarray
hudson
et
al
use
commerci
highdens
protein
microarray
protoarray
human
protein
microarray
invitrogen
contain
human
protein
orf
human
protein
express
ntermin
gstfusion
protein
print
duplic
nitrocellulos
slide
author
screen
sera
healthi
individu
individu
suffer
ovarian
cancer
differ
tumor
stage
motiv
studi
common
ovariancanc
marker
satisfactorili
predict
patient
earlystag
diseas
stage
ii
thu
goal
studi
identifi
protein
biomark
earli
diseas
state
biomark
may
later
becom
use
cancer
therapi
prognosi
base
proteinmicroarray
approach
microarray
screen
protein
reveal
bound
autoantibodi
diseas
individu
bound
autoantibodi
healthi
individu
protein
bound
select
autoantibodi
cancer
patient
wherea
bound
select
healthi
individu
unfortun
antigen
antigen
combin
identifi
bound
exclus
sera
either
cancer
patient
healthi
individu
studi
howev
tumorassoci
autoantigen
two
antigen
associ
healthi
state
could
identifi
statist
method
four
antigen
lamin
ac
structurespecif
recognit
protein
ralbind
protein
select
protein
exhibit
strongest
varianc
diseas
healthi
individu
valid
studi
immunoblot
analysi
tissu
microarray
use
valid
three
four
candid
biomark
prove
use
biopsi
analysi
thu
potenti
protein
microarray
biomark
discoveri
clearli
demonstr
studi
remain
proven
howev
whether
approach
also
feasibl
routin
screen
sera
snyder
cowork
employ
proteinmicroarray
approach
identifi
antibodi
human
sever
acut
respiratori
syndrom
sar
relat
coronavirus
sera
two
patient
group
sampl
obtain
inhabit
canada
china
accuraci
gener
gstfusion
protein
yeast
spot
reversephas
protein
array
nitrocellulos
slide
schleicher
schuell
proteinmicroarray
analysi
possibl
differenti
sar
two
human
coronavirus
screen
patient
sera
valid
statist
method
elisa
proteinmicroarray
approach
found
least
similar
sensit
standard
elisa
test
even
specif
furthermor
multipl
antigen
differ
coronavirus
test
simultan
longterm
monitor
serum
reactiv
select
sampl
figur
reveal
figur
schemat
represent
forwardphas
protein
array
fppa
reversephas
protein
array
rppa
fppa
specif
protein
sampl
contain
varieti
protein
captur
specif
antibodi
immobil
differ
spot
microarray
array
incub
one
sampl
b
either
label
second
antibodi
left
label
analyt
protein
right
use
readout
fppa
multipl
analyt
endpoint
detect
one
sampl
c
rppa
sampl
eg
patient
sampl
cell
lysat
contain
varieti
protein
spot
microarray
format
spot
array
differ
sampl
immobil
thu
hundr
sampl
contain
one
microarray
detect
rppa
one
label
antibodi
specif
certain
protein
use
signal
gener
amplif
thu
endpoint
analysi
one
analyt
monitor
across
hundr
sampl
figur
protein
epitop
signatur
tag
prest
protein
sequenc
larg
enough
contain
good
epitop
small
enough
express
escherichia
coli
gener
care
computerassist
select
prest
express
host
immun
obtain
polyclon
antibodi
purifi
care
affin
purif
correspond
prest
give
highqual
monospecif
antibodi
reproduc
refer
chemi
patient
show
reactiv
antibodi
longer
period
time
day
thu
studi
demonstr
power
proteinmicroarraybas
method
biomed
diagnost
anderson
et
al
monitor
tumor
antigen
breast
cancer
microarray
display
antigen
construct
nucleicacidprogram
protein
array
nappa
technolog
figur
nappa
reli
situ
express
protein
immobil
dna
templat
chip
surfac
thu
problem
aris
protein
isol
purif
storag
print
elisa
applic
reduc
furthermor
multiplex
enabl
howev
nappa
approach
labori
lead
impur
protein
array
contain
dna
plasmid
captur
antibodi
gener
gst
protein
sera
breastcanc
patient
test
antibodi
result
confirm
success
elisa
western
blot
select
exampl
describ
mani
studi
illustr
nice
protein
microarray
use
tool
biomark
discoveri
futur
research
show
whether
biomark
discov
technolog
suffici
indic
reliabl
becom
use
tool
clinic
diagnost
pharmaceut
applic
number
vitro
method
includ
affin
chromatographi
proteindisplay
technolog
phage
display
use
target
identif
valid
protein
microarray
often
use
combin
vivo
screen
wholecel
model
despit
advantag
offer
biochip
analys
tradit
use
affin
chromatographi
exampl
proteinmicroarray
applic
target
identif
still
scarc
affin
chromatographi
timeconsum
process
bias
toward
highabund
protein
protein
prone
obscur
bind
lowabund
protein
immobil
smallmolecul
ligand
could
thu
falsifi
result
protein
microarray
suffer
problem
sinc
display
protein
equal
amount
furthermor
enabl
fast
readout
principl
amen
parallel
screen
schreiber
cowork
report
use
protein
microarray
target
deconvolut
smallmolecul
highthroughput
screen
preliminari
phenotypebas
chemic
genet
suppressor
assay
small
antibodi
success
detect
sera
label
secondari
antibodi
wherea
neg
sera
show
signal
c
comparison
detect
sensit
elisa
nappa
reprint
adapt
permiss
refer
copyright
american
chemic
societi
molecul
screen
abil
rescu
cell
growth
yeast
cell
expos
antiprolif
drug
rapamycin
author
identifi
six
smallmolecul
inhibitor
rapamycin
smir
two
use
subsequ
yeast
proteom
chip
identifi
respect
protein
target
array
display
yeast
protein
close
entir
yeast
proteom
obtain
print
polyhistidineand
gsttag
yeast
protein
aldehydeor
nickelco
slide
biotinyl
variant
two
smir
synthes
incub
proteom
chip
smir
bind
protein
chip
surfac
detect
fluoresc
label
streptavidin
way
author
abl
identifi
new
unknown
member
target
rapamycin
tor
signal
network
besid
target
identif
activ
profil
small
molecul
also
consider
interest
drug
discoveri
activitybas
profil
abp
enabl
elucid
enzym
activ
complex
biolog
mixtur
activitybas
probe
bind
irrevers
activ
enzym
subsequ
detect
report
tag
combin
abp
proteinmicroarray
technolog
enabl
quantit
fingerprint
inhibitor
set
immobil
enzym
highthroughput
fashion
miyak
cowork
creat
microarray
six
proteas
cathepsin
cystein
proteas
famili
screen
smallmolecul
inhibitor
includ
eight
known
cystein
proteas
inhibitor
figur
highthroughput
competit
assay
proteas
microarray
preincub
inhibitor
subsequ
fluoresc
affin
label
fal
fluorophorelabel
irrevers
cystein
proteas
inhibitor
ad
fal
compet
preincub
inhibitor
bind
immobil
enzym
wash
step
level
residu
fluoresc
gave
inform
bind
characterist
preincub
inhibitor
inhibit
eight
known
cystein
proteas
inhibitor
found
inhibit
profil
fingerprint
correspond
literatur
valu
second
set
experi
miyak
cowork
screen
cystein
proteas
inhibitor
concentrationdepend
manner
obtain
inhibit
constant
quantit
kinet
data
inhibit
constant
obtain
assay
agreement
known
literatur
data
yao
cowork
optim
extend
approach
use
proteas
microarray
divid
subarray
abl
carri
quantit
inhibitor
fingerprint
multipl
proteas
time
experi
gave
addit
inform
inhibitor
select
protein
microarray
also
use
drug
discoveri
determin
smallmoleculeprotein
interact
indirectli
exampl
antibodi
array
use
determin
influenc
drug
proteom
organ
compar
proteinexpress
level
presenc
absenc
drug
interest
sokolov
cadet
appli
microarray
technolog
investig
correl
proteinexpress
level
behavior
phenotyp
mice
treat
methamphetamin
interest
identifi
neuron
adapt
possibl
associ
abus
methamphetamin
human
abus
methamphetamin
known
caus
aggress
behavior
human
varieti
anim
cat
rodent
nonhuman
primat
comparison
control
group
found
increas
aggress
locomot
mice
treat
chronic
methamphetamin
sever
week
proteinexpress
level
compar
use
commerci
avail
antibodi
array
display
monoclon
antibodi
includ
antibodi
relat
signal
transduct
neurobiolog
brain
tissu
reprint
permiss
refer
copyright
macmillan
publish
ltd
natur
biotechnolog
angewandt
chemi
remov
mice
protein
extract
label
fluoresc
dye
incub
antibodi
array
data
evalu
show
downregul
seven
protein
upregul
one
protein
among
protein
princip
compon
mitogenactiv
protein
map
kinas
pathway
inhibitor
protein
kinas
c
togeth
followup
kinas
screen
result
hint
involv
map
kinas
pathway
behavior
chang
also
observ
anim
model
although
studi
requir
result
clearli
demonstr
applic
microarraybas
approach
despit
advantag
offer
protein
microarray
facil
fast
highthroughput
analysi
thousand
sampl
parallel
applic
protein
microarray
drug
discoveri
remain
limit
far
broader
applic
possibl
standard
technolog
probabl
requir
simplertous
morerobust
proteinmicroarray
platform
avail
present
well
establish
standard
procedur
data
analysi
qualiti
control
advent
moreadvanc
method
prepar
protein
biochip
combin
slow
steadi
improv
standard
proteinmicroarray
protocol
suggest
use
protein
biochip
drug
discoveri
increas
aim
minireview
highlight
state
art
applic
proteinbiochip
technolog
grow
number
success
exampl
proteinbiochip
applic
surfac
across
mani
differ
research
area
excit
advanc
field
biosensor
develop
tissu
engin
base
directli
protein
biochip
nevertheless
requir
control
protein
immobil
substrat
biosensor
promis
direct
sensit
rapid
analysi
complex
sampl
medic
sampl
current
subject
timeand
materialintens
techniqu
eg
elisa
thu
biosensor
could
revolution
analysi
complex
sampl
healthcar
medicin
life
scienc
variou
approach
includ
method
base
nanowir
surfac
plasmon
reson
microcantilev
shown
promis
result
regard
research
group
whitesid
niemey
independ
describ
fabric
rout
toward
afford
dispos
biosensor
platform
lieber
cowork
demonstr
use
nanowirebas
fieldeffect
transistor
electr
detect
distinct
diseasemark
protein
clinic
relev
serum
sampl
approach
could
eventu
facilit
pattern
analysi
exist
emerg
biomark
diagnosi
matric
immobil
morphogen
protein
usual
use
tissu
engin
structur
support
cell
bone
skin
articular
cartilag
vascular
tissu
also
use
neuralstemcel
expans
iwata
cowork
develop
enhanc
cellcultur
substrat
select
growth
neural
stem
cell
nsc
display
artifici
dimer
epiderm
growth
factor
strong
activ
nsc
prolifer
approach
could
significantli
enhanc
cellgrowth
rate
rel
observ
usual
method
radis
cowork
success
assembl
endotheli
cell
threedimension
collagen
scaffold
function
vascular
endotheli
growth
factor
vegf
thu
demonstr
vascular
larg
threedimension
tissu
construct
would
requir
ensur
oxygen
suppli
might
possibl
immobil
vegf
despit
larg
number
success
exampl
applic
protein
biochip
biomed
biotechnolog
research
numer
challeng
remain
tackl
protein
biochip
current
prepar
tradit
strategi
lead
random
protein
orient
chip
surfac
random
arrang
neg
influenc
protein
activ
ligand
bind
result
steric
hindranc
thu
lead
decreas
assay
effici
even
falsif
assay
result
problem
might
solv
implement
moreadvanc
method
prepar
protein
biochip
mani
method
develop
last
year
express
purif
thousand
protein
retent
intrins
activ
far
trivial
howev
grow
number
approach
fast
product
highqual
proteomescal
protein
biochip
develop
sever
organ
one
exampl
fulllength
expressionreadi
gene
collect
flexgen
consist
completeorf
plasmid
collect
variou
speci
simpl
clone
express
whole
proteom
introduct
labelfre
detect
method
mass
spectrometri
surfac
plasmon
reson
spr
simplifi
microarray
analysi
sinc
interact
partner
longer
need
label
featur
particularli
import
largescal
analysi
base
protein
biochip
evansnguyen
et
al
incub
superhydrophob
selfassembledmonolayermodifi
porou
gold
surfac
display
immobil
antibodi
plasma
spike
antigen
peptid
matrix
applic
detect
bound
peptid
directli
use
maldi
campbel
kim
review
promis
applic
spr
labelfre
readout
proteinprotein
interact
protein
microarray
standard
microarray
product
applic
data
analysi
would
improv
ensur
qualiti
data
obtain
protein
microarray
standard
would
includ
subsequ
confirmatori
studi
independ
method
verifi
find
proteinmicroarray
screen
none
challeng
insurmount
much
progress
made
last
decad
expect
proteinbiochip
technolog
verg
breakthrough
becom
standard
tool
research
much
dnamicroarray
technolog
today
thank
sabin
borgmann
contribut
origin
draft
manuscript
laura
koch
c
niemey
h
waldmann
et
al
